Organogenesis (ORGO) Expected to Announce Quarterly Earnings on Thursday

Organogenesis (NASDAQ:ORGO) is expected to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $109.60 million for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Organogenesis Trading Up 0.9 %

Organogenesis stock opened at $3.21 on Wednesday. The firm has a 50 day moving average of $3.37 and a 200 day moving average of $3.22. The firm has a market capitalization of $403.58 million, a price-to-earnings ratio of -53.50 and a beta of 1.77. Organogenesis has a 12-month low of $2.16 and a 12-month high of $4.57. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21.

Insider Buying and Selling

In other Organogenesis news, CEO Gary S. Gillheeney sold 55,615 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the completion of the transaction, the chief executive officer now directly owns 3,044,779 shares in the company, valued at $10,230,457.44. This represents a 1.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 278,116 shares of company stock valued at $991,190. 36.90% of the stock is owned by corporate insiders.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.